Poland· PL-100403947
Segluromet
A metformin and ertugliflozin product containing ertugliflozinum + metformini hydrochloridum, registered in Poland by Merck Sharp & Dohme B.V.. The same ATC class is registered in 8 of our 19 countries.
Checked against URPL (Poland) on
Informational only — not a medical device.
Where it is registered
Metformin and ertugliflozin is registered in 8 of 19 countries.
Countries holding a registration under ATC A10BD23 (metformin and ertugliflozin), each read from that country’s own register.
- This record: Poland, from URPL (Poland)
- 5 of them publish a price we can compare per daily dose
Metformin and ertugliflozin · ATC A10BD23
8 / 19 countries
- Belgiumprice
- Czechiaprice
- Denmark
- Finlandprice
- Icelandprice
- Ireland
- Netherlands
- Polandprice
The record
At a glance
URPL (Poland)- Active substance
- Ertugliflozinum + Metformini hydrochloridum
- Manufacturer
- Merck Sharp & Dohme B.V.
- Country
- Poland (PL)
- ATC code
- A10BD23
- ATC class
- Metformin and ertugliflozin
- Reimbursed
- Not published by this register
- Source register
- URPL (Poland)
- Last checked
- September 27, 2026
Packs & prices · 0
No packs listed by the register for this record.
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
Metformin and ertugliflozin in 4 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- CzechiaSEGLUROMETMerck Sharp & Dohme B.V., Haarlem
- IcelandSeglurometMerck Sharp & Dohme B.V.*
- SwedenSegluromet 2,5 mg/1000 mg Filmdragerad tablettMerck Sharp & Dohme BV
- SpainSEGLUROMET 2,5 MG/1.000 MG COMPRIMIDOS RECUBIERTOS CON PELICULAMerck Sharp & Dohme B.V.
Authorised across Europe · EMA
The same active substance is authorised in 3 EEA countries. Names it is sold under:
- Iceland · Segluromet
- Liechtenstein · Segluromet
- Norway · Segluromet
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of URPL (Poland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/18416e05-2791-41d0-a3c5-99a3b9ce1503 GET /v1/drugs/18416e05-2791-41d0-a3c5-99a3b9ce1503?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Tabletki powlekane",
"source": "urpl",
"strength": "2,5 mg + 850 mg",
"packaging": "Rp ¦ EU/1/18/1265/001 ¦ 127685\n14 tabl.\nRp ¦ EU/1/18/1265/002 ¦ 127686\n28 tabl.\nRp ¦ EU/1/18/1265/003 ¦ 127687\n30 tabl. (30 x 1)\nRp ¦ EU/1/18/1265/004 ¦ 127688\n56 tabl.\nRp ¦ EU/1/18/1265/005 ¦ 127689\n60 tabl.\nRp ¦ EU/1/18/1265/006 ¦ 127690\n168 tabl.\nRp ¦ EU/1/18/1265/007 ¦ 127691\n180 tabl.\nRp ¦ EU/1/18/1265/029 ¦ 131607\n196 tabl.",
"substance": "Ertugliflozinum 2.5 mg + Metformini hydrochloridum 850 mg",
"common_name": "Ertugliflozinum + Metformini hydrochloridum",
"pl_product_id": "100403947",
"pozwolenie_nr": null,
"auth_procedure": "CEN",
"authorisation_validity": null
}See everything about metformin and ertugliflozin.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.